Total hip/knee arthroplasty
Conditions
Interventions
Doxazosin group:Doxazosin 4 mg the morning of surgery once
Placebo group:Placebo 4 mg the morning of surgery once
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
35 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Unilateral primary hip/knee replacement is planned; 2. Male, over 35 years old; 3. The ASA classification is less than 3.
Exclusion criteria
Exclusion criteria: 1. Doxazosin allergy; 2. Patients with preoperative or intraoperative indwelling catheterization, recent myocardial infarction, history of gastrointestinal cavity constriction, and high preoperative inflammatory factors (CRP > 20 mg/L); 3. Abnormal platelet function or coagulation function before surgery; 4. Abnormal liver and kidney function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative urinary retention; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay;Postoperative infection;Postoperative Visual Analog Scale Ratings;Opioid usage;American Urological Association Symptom Score; | — |
Countries
China
Contacts
Public ContactZongke Zhou
West China Hospital, Sichuan University
Outcome results
None listed